Table 1.

Mean flurbiprofen kinetic parameter estimates^*

Variable	Units	Visit A	Visit B	Visit C
AUC∞	µg l−1 h−1	50.6 ± 17.6	109.3 ± 34.4†	141.9 ± 34.2†
CL/F	l h−1	1.09 ± 0.35	0.50 ± 0.16†	0.38 ± 0.11†
Cmax	µg ml−1	9.4 ± 2.5	11.7 ± 2.3	12.9 ± 2.8‡
Tlag	h	0.31 ± 0.47	0.13 ± 0.13	0.19 ± 0.19
Tmax	h	2.3 ± 1.0	1.9 ± 0.8	1.9 ± 0.6
V/F	l	6.12 ± 1.11	5.45 ± 1.06	5.00 ± 0.92‡
T1/2	h	4.3 ± 1.6	8.0 ± 2.0†	9.5 ± 1.6†
4OHCLf	l h−1	0.369 ± 0.190	0.120 ± 0.068†	0.091 ± 0.048†
FGCLf		0.144 ± 0.042	0.104 ± 0.041†	0.084 ± 0.038†
8-h FLRR		0.652 ± 0.109	0.432 ± 0.146†	0.396 ± 0.127†
8-h FLMR		2.315 ± 1.731	0.912 ± 0.686‡	0.744 ± 0.481†

Data are mean values ± SD. Visit A, flurbiprofen 50 mg alone; visit B, flurbiprofen 50 mg + fluconazole 400 mg; and visit C, flurbiprofen 50 mg after 7 days fluconazole 400 mg daily. AUC_∞, area under the plasma concentration–time curve extrapolated to infinity; CL/F, total clearance; 4OHCLf, 4′-hydroxyflurbiprofen formation clearance; FGCLf, sum of flurbiprofen glucuronide formation clearance and flurbiprofen renal clearance; FLRR, flurbiprofen recovery ratio = 4′-OHF/4′-OHF+ F; FLMR, flurbiprofen metabolic ratio = 4′-OHF/F.

^*There were no statistically significant differences in the comparison between visit B and visit C.

^†Comparison between visit B or visit C and visit A: P < 0.001.

^‡Comparison between visit B or visit C and visit A: P < 0.05.